Transplantation Proceedings
Volume 39, Issue 3 , Pages 602-605 , April 2007

Converting to a Generic Formulation of Mycophenolate Mofetil in Stable Kidney Transplant Recipients: 1 Year of Drug Surveillance and Outcome

  • C. Videla

      Affiliations

    • Corresponding Author InformationAddress reprint requests to C. Videla, MD, 5 Norte 1053 Vina del Mar, Postal Code 2531604, Chile.
    • ,
  • C. Godoy

References 

  1. Danovitch GM. Mycophenolate mofetil (A decade of clinical significance). Transplantation. 2005;80:272
  2. Denton MD, Magee CM, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet. 1999;353:1083
  3. David-Neto E, Pereira LM, Kakehashi E, et al. The need of mycophenolic acid monitoring in long-term renal transplants. Clin Transplant. 2005;19:19
  4. Cattaneo D, Gaspari F, Ferrari S, et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant. 2001;15:402
  5. Foradori A, Mezzano S, Videla C, et al. Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazole in stable adult kidney transplants. Transplant Proc. 1998;30:1685
  6. Srinivas TR, Meier-Kriesche H, Kaplan B. Pharmacokinetics principles of immunosuppressive drugs. Am J Transplant. 2005;5:207
  7. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodinamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant. 2003;3:534
  8. Hesselink DA, Van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5:987
  9. Videla C, Vega J, Borja H. Hepatotoxicity associated with cyclosporine monitoring using C2 recommendations in adult renal recipients receiving ketoconazole. Transplant Proc. 2005;37:1574
  10. Van Hest RM, Mathot RA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mophetil dosing a population pharmacokinetic meto-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006;17:871
  11. Mourad M, Malaise J, Chaib Eddour D, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem. 2001;47:88
  12. Engelbertink R, Gregoor PS, Hesse J, et al. High mycophenolic acid area under-the-curve values in renal transplant recipients on long-term mycophenolate mofetil treatment. Transplant Proc. 2002;34:2983

PII: S0041-1345(06)01581-8

doi: 10.1016/j.transproceed.2006.12.034

Transplantation Proceedings
Volume 39, Issue 3 , Pages 602-605 , April 2007

Article Tools

* Image Usage & Resolution